BMY Receives EC Approval for Expanded Label of CAR T Cell Therapy Breyanzi
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Source: NASDAQ.COM
Bristol Myers Squibb Approval: The European Commission approved Breyanzi for treating adult patients with relapsed or refractory mantle cell lymphoma, marking its fourth approval in Europe for various lymphomas.
Clinical Trial Results: The approval is based on the TRANSCEND NHL 001 trial, showing an 82.7% response rate and 71.6% complete response rate among patients treated with Breyanzi.
Market Impact and Pipeline Expansion: Bristol Myers is focusing on expanding its drug pipeline due to challenges from generics affecting its legacy products, with recent share gains following positive news from Bayer's stroke prevention candidate.
Discontinuation of Librexia Study: Bristol Myers and Johnson & Johnson halted the Librexia study for milvexian after an interim analysis indicated it would not meet efficacy endpoints, but other studies for milvexian will continue as planned.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 263.040
Low
190.00
Averages
218.50
High
240.00
Current: 263.040
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Earnings Expectations Drive JNJ Stock Up
- Earnings Release Announcement: Johnson & Johnson (JNJ) is set to release its Q2 earnings on July 15, with analysts forecasting earnings of $2.85 per share and revenue of $25.05 billion, indicating the company's robust performance in the market.
- Positive Stock Reaction: Ahead of the earnings report, JNJ's stock rose by 3.6%, reflecting investor optimism regarding the upcoming financial results, which could further drive the company's stock price upward.
- Market Expectation Analysis: Analysts' earnings expectations for JNJ suggest that despite facing market challenges, the company is still able to maintain strong profitability, which will enhance investor confidence and attract more capital inflows.
- Strategic Implications: JNJ's earnings report will provide critical data for its future strategic direction, and if actual performance exceeds expectations, it could further solidify its leadership position in the healthcare industry.
See More
Market Rotation Creates Buying Opportunities, Says Jim Cramer
- Market Rotation Insight: Jim Cramer highlights that the recent market rotation has created buying opportunities for high-quality stocks, as many quality companies have been pulled lower by institutional selling despite their unchanged fundamentals, urging investors to seize this moment.
- Stock Recommendations: Cramer specifically points to PepsiCo, suggesting that its recent pullback offers a favorable entry point ahead of its July 9 earnings report, while he also sees potential in Starbucks as its CEO works on a successful turnaround.
- Risky Investment Opportunities: For investors willing to take on more risk, Cramer emphasizes Constellation Brands, noting that despite ongoing concerns about spirits, its beer business appears to be stabilizing, making it worth a look.
- Consumer and AI Dynamics: Cramer mentions that TJX Companies will benefit from weakened consumer spending as an off-price retailer capitalizes on excess inventory from traditional retailers, while a rebound in AI stocks has negatively impacted healthcare stocks, including Johnson & Johnson.
See More
Market Rotation Creates Buying Opportunities for Quality Stocks
- Investment Opportunity: CNBC's Jim Cramer highlighted that the latest market rotation presents buying opportunities for high-quality companies that have been unfairly dragged down by institutional selling, urging investors to seize this moment.
- Stock Recommendations: Cramer specifically mentioned Johnson & Johnson, PepsiCo, Starbucks, Constellation Brands, and TJX as stocks that are undervalued amid market fluctuations, making them worthy of investor attention.
- Market Dynamics: Following last week's jobs report indicating a slowdown in hiring, many large money managers repositioned their portfolios, leading to a drop in high-quality stock prices, which Cramer believes creates a favorable buying environment.
- Sector Impact: Cramer emphasized that discount retailers like TJX may benefit from weakened consumer spending, as excess inventory at traditional retailers provides them with more discounted merchandise, enhancing their competitive edge in the market.
See More
Analysis of Retirement Income Growth Strategies
- Income Growth Potential: Starting with a 3.5% yield and assuming an 8% annual growth, a $35,000 income can grow to approximately $140,000 in 20 years, highlighting the critical importance of compounding effects in long-term retirement income.
- High-Yield Risks: High-yield instruments like mortgage REITs may offer substantial initial income, but as principal erodes, retirees will face significant purchasing power loss over a 25-year retirement, underscoring the need for stable growth investments.
- Advantages of Dividend Growth: Companies like Johnson & Johnson and Procter & Gamble have consistently raised dividends over the past decade, achieving 175% and 70 years of dividend growth respectively, demonstrating the effectiveness of dividend growth strategies in long-term investing.
- Capital Requirement Analysis: To achieve an annual income of $60,000, a 3.5% yield requires approximately $1.714 million in capital, while a 12% yield only needs $500,000; although high yields seem attractive, stable growth investments may prove more advantageous in the long run.
See More
Long-Term Investment Strategy in Healthcare Sector
- Strong Financial Performance: Johnson & Johnson reported Q1 revenue of $24.1 billion, a 9.9% increase year-over-year, with adjusted EPS of $2.70 exceeding analyst expectations, and it forecasts annual sales between $99.7 billion and $100.7 billion, indicating robust growth potential in innovative medicine and medtech.
- Diversification Advantage: Abbott Laboratories achieved Q1 sales of $11.2 billion, up 7.8% year-over-year, with strong performance in medical devices and diagnostics offsetting declines in nutrition, and it expects full-year revenue growth of 6.5% to 7.5%, solidifying its position in global healthcare demand.
- Market Dominance: UnitedHealth Group's Q1 revenue reached $111.7 billion, a 2% increase year-over-year, with its Optum division leveraging data analytics and pharmacy care for vertical integration, projecting full-year EPS exceeding $17.35, up at least 31%, reinforcing its leadership in the U.S. private health insurance market.
- Stable Dividend Returns: Johnson & Johnson, Abbott, and UnitedHealth Group are all Dividend Kings, having increased dividends for 64, 54, and 17 consecutive years respectively, showcasing their strong cash flow management and appeal to long-term investors, particularly in times of economic uncertainty, providing low volatility and high margin of safety.
See More
Navan, Johnson & Johnson, and CrowdStrike Stocks Hit Record Highs
- Navan Stock Surge: Navan shares hit a record high of $25.85 on Thursday following the launch of its Model Context Protocol (MCP), which allows businesses to connect AI models directly to travel and expense data, enhancing user experience and competitive positioning in the market.
- Johnson & Johnson Attracts Defensive Buyers: Johnson & Johnson's stock reached an all-time high of $263.10 as investors sought defensive stocks amid market caution, bolstered by the company's raised 2026 financial outlook, which reassured investors despite economic uncertainties.
- CrowdStrike Benefits from Stock Split: CrowdStrike shares soared to a record high of $199.53 on Thursday after completing a 4-for-1 stock split, making the stock more accessible to a broader range of investors and fueling optimism about the company's expanding recurring revenue base.
- Market Performance Comparison: Year-to-date, Johnson & Johnson shares have risen 27%, while CrowdStrike and Navan stocks have surged 65% and 50%, respectively, reflecting strong investor confidence and demand for these companies in the current market environment.
See More
Strong Earnings Expectations Drive JNJ Stock Up
- Earnings Release Announcement: Johnson & Johnson (JNJ) is set to release its Q2 earnings on July 15, with analysts forecasting earnings of $2.85 per share and revenue of $25.05 billion, indicating the company's robust performance in the market.
- Positive Stock Reaction: Ahead of the earnings report, JNJ's stock rose by 3.6%, reflecting investor optimism regarding the upcoming financial results, which could further drive the company's stock price upward.
- Market Expectation Analysis: Analysts' earnings expectations for JNJ suggest that despite facing market challenges, the company is still able to maintain strong profitability, which will enhance investor confidence and attract more capital inflows.
- Strategic Implications: JNJ's earnings report will provide critical data for its future strategic direction, and if actual performance exceeds expectations, it could further solidify its leadership position in the healthcare industry.
See More
Market Rotation Creates Buying Opportunities, Says Jim Cramer
- Market Rotation Insight: Jim Cramer highlights that the recent market rotation has created buying opportunities for high-quality stocks, as many quality companies have been pulled lower by institutional selling despite their unchanged fundamentals, urging investors to seize this moment.
- Stock Recommendations: Cramer specifically points to PepsiCo, suggesting that its recent pullback offers a favorable entry point ahead of its July 9 earnings report, while he also sees potential in Starbucks as its CEO works on a successful turnaround.
- Risky Investment Opportunities: For investors willing to take on more risk, Cramer emphasizes Constellation Brands, noting that despite ongoing concerns about spirits, its beer business appears to be stabilizing, making it worth a look.
- Consumer and AI Dynamics: Cramer mentions that TJX Companies will benefit from weakened consumer spending as an off-price retailer capitalizes on excess inventory from traditional retailers, while a rebound in AI stocks has negatively impacted healthcare stocks, including Johnson & Johnson.
See More
Market Rotation Creates Buying Opportunities for Quality Stocks
- Investment Opportunity: CNBC's Jim Cramer highlighted that the latest market rotation presents buying opportunities for high-quality companies that have been unfairly dragged down by institutional selling, urging investors to seize this moment.
- Stock Recommendations: Cramer specifically mentioned Johnson & Johnson, PepsiCo, Starbucks, Constellation Brands, and TJX as stocks that are undervalued amid market fluctuations, making them worthy of investor attention.
- Market Dynamics: Following last week's jobs report indicating a slowdown in hiring, many large money managers repositioned their portfolios, leading to a drop in high-quality stock prices, which Cramer believes creates a favorable buying environment.
- Sector Impact: Cramer emphasized that discount retailers like TJX may benefit from weakened consumer spending, as excess inventory at traditional retailers provides them with more discounted merchandise, enhancing their competitive edge in the market.
See More
Analysis of Retirement Income Growth Strategies
- Income Growth Potential: Starting with a 3.5% yield and assuming an 8% annual growth, a $35,000 income can grow to approximately $140,000 in 20 years, highlighting the critical importance of compounding effects in long-term retirement income.
- High-Yield Risks: High-yield instruments like mortgage REITs may offer substantial initial income, but as principal erodes, retirees will face significant purchasing power loss over a 25-year retirement, underscoring the need for stable growth investments.
- Advantages of Dividend Growth: Companies like Johnson & Johnson and Procter & Gamble have consistently raised dividends over the past decade, achieving 175% and 70 years of dividend growth respectively, demonstrating the effectiveness of dividend growth strategies in long-term investing.
- Capital Requirement Analysis: To achieve an annual income of $60,000, a 3.5% yield requires approximately $1.714 million in capital, while a 12% yield only needs $500,000; although high yields seem attractive, stable growth investments may prove more advantageous in the long run.
See More
Long-Term Investment Strategy in Healthcare Sector
- Strong Financial Performance: Johnson & Johnson reported Q1 revenue of $24.1 billion, a 9.9% increase year-over-year, with adjusted EPS of $2.70 exceeding analyst expectations, and it forecasts annual sales between $99.7 billion and $100.7 billion, indicating robust growth potential in innovative medicine and medtech.
- Diversification Advantage: Abbott Laboratories achieved Q1 sales of $11.2 billion, up 7.8% year-over-year, with strong performance in medical devices and diagnostics offsetting declines in nutrition, and it expects full-year revenue growth of 6.5% to 7.5%, solidifying its position in global healthcare demand.
- Market Dominance: UnitedHealth Group's Q1 revenue reached $111.7 billion, a 2% increase year-over-year, with its Optum division leveraging data analytics and pharmacy care for vertical integration, projecting full-year EPS exceeding $17.35, up at least 31%, reinforcing its leadership in the U.S. private health insurance market.
- Stable Dividend Returns: Johnson & Johnson, Abbott, and UnitedHealth Group are all Dividend Kings, having increased dividends for 64, 54, and 17 consecutive years respectively, showcasing their strong cash flow management and appeal to long-term investors, particularly in times of economic uncertainty, providing low volatility and high margin of safety.
See More
Navan, Johnson & Johnson, and CrowdStrike Stocks Hit Record Highs
- Navan Stock Surge: Navan shares hit a record high of $25.85 on Thursday following the launch of its Model Context Protocol (MCP), which allows businesses to connect AI models directly to travel and expense data, enhancing user experience and competitive positioning in the market.
- Johnson & Johnson Attracts Defensive Buyers: Johnson & Johnson's stock reached an all-time high of $263.10 as investors sought defensive stocks amid market caution, bolstered by the company's raised 2026 financial outlook, which reassured investors despite economic uncertainties.
- CrowdStrike Benefits from Stock Split: CrowdStrike shares soared to a record high of $199.53 on Thursday after completing a 4-for-1 stock split, making the stock more accessible to a broader range of investors and fueling optimism about the company's expanding recurring revenue base.
- Market Performance Comparison: Year-to-date, Johnson & Johnson shares have risen 27%, while CrowdStrike and Navan stocks have surged 65% and 50%, respectively, reflecting strong investor confidence and demand for these companies in the current market environment.
See More
